236 related articles for article (PubMed ID: 32001139)
1. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.
Ye M; Zhang Q; Chen Y; Fu Q; Li X; Bai X; Liang T
HPB (Oxford); 2020 Jun; 22(6):821-832. PubMed ID: 32001139
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
Huan L; Yu F; Cao D; Zhou H; Qin M; Cao Y
PLoS One; 2024; 19(3):e0295983. PubMed ID: 38451955
[TBL] [Abstract][Full Text] [Related]
3. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X
World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339
[TBL] [Abstract][Full Text] [Related]
4. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
[TBL] [Abstract][Full Text] [Related]
5. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study.
Su YY; Chao YJ; Wang CJ; Liao TK; Su PJ; Huang CJ; Chiang NJ; Yu YT; Tsai HM; Chen LT; Shan YS
Int J Surg; 2023 Sep; 109(9):2614-2623. PubMed ID: 37300888
[TBL] [Abstract][Full Text] [Related]
6. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
7. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
[TBL] [Abstract][Full Text] [Related]
8. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis.
Gosavi R; Chia C; Michael M; Heriot AG; Warrier SK; Kong JC
Int J Colorectal Dis; 2021 Oct; 36(10):2063-2070. PubMed ID: 33945007
[TBL] [Abstract][Full Text] [Related]
11. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials.
Uson Junior PLS; Dias E Silva D; de Castro NM; da Silva Victor E; Rother ET; Araújo SEA; Borad MJ; Moura F
ESMO Open; 2023 Feb; 8(1):100771. PubMed ID: 36638709
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review.
Ren X; Wei X; Ding Y; Qi F; Zhang Y; Hu X; Qin C; Li X
Onco Targets Ther; 2019; 12():733-744. PubMed ID: 30774360
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
Liu S; Li H; Xue Y; Yang L
PLoS One; 2023; 18(9):e0290888. PubMed ID: 37672511
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis.
Chen Y; Shi XE; Tian JH; Yang XJ; Wang YF; Yang KH
Medicine (Baltimore); 2018 May; 97(20):e10634. PubMed ID: 29768327
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.
Ge L; Wang HJ; Yin D; Lei C; Zhu JF; Cai XH; Zhang GQ
World J Gastroenterol; 2012 Dec; 18(48):7384-93. PubMed ID: 23326149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]